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Objectives The aim of this study was to evaluate the efﬁcacy of regadenoson, in comparison with
adenosine, for assessing fractional ﬂow reserve (FFR) of intermediate coronary artery stenoses (CAS).
Background Fractional ﬂow reserve is an established invasive method for assessing the physiologi-
cal signiﬁcance of CAS. Regadenoson, a selective A2A receptor agonist, is an approved hyperemic
gent for pharmacological stress imaging, but its role for measuring FFR is unknown.
ethods This prospective, single-center study enrolled 25 consecutive patients with intermediate
AS discovered during elective angiography (25 lesions). In each patient, FFR of the CAS was mea-
ured ﬁrst by IV adenosine (140 g/kg/min), followed by IV regadenoson (400 g bolus). The in-
trapatient FFR correlation between adenosine and regadenoson was evaluated.
Results The mean age was 63  11 years, and mean left ventricular ejection fraction was 58 
11%. Most patients were male (52%) and had hypertension (84%) and dyslipidemia (84%), with 24%
having diabetes mellitus and 20% chronic obstructive pulmonary disease. The CAS was visually esti-
mated during angiography (mean 58  9%) and most often found in the left anterior descending
coronary artery (48%). A strong, linear correlation of FFR was noted with adenosine and regade-
noson (r  0.985, p  0.001). A hemodynamically signiﬁcant lesion (FFR 0.80) was present in 52%
with no reclassiﬁcation of signiﬁcance between adenosine and regadenoson. No serious events oc-
curred with administration of either drug.
Conclusions Our results suggest that a single IV bolus of regadenoson is as effective as an intrave-
nous infusion of adenosine for measuring FFR and, given its ease of use, should be considered for
FFR measurement in the catheterization laboratory. (J Am Coll Cardiol Intv 2011;4:1085–92) © 2011
by the American College of Cardiology Foundation
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1086Progressive luminal narrowing from coronary artery disease
(CAD) can lead to myocardial ischemia and yield unfavor-
able clinical outcomes (1–3). Decisions to revascularize are
based, in part, upon the presence of a hemodynamically
significant coronary artery stenosis (CAS). In the absence of
inducible ischemia in patients with known CAD, medical
therapy alone is often sufficient, because there is no known
additive benefit with revascularization (3–5).
See page 1093
The pressure-derived fractional flow reserve (FFR) is a
well-established invasive index for assessing the physiolog-
ical significance of a CAS (6). It is defined as the ratio of
maximal achievable hyperemic-induced blood flow in a
stenotic coronary artery to normal maximal flow in the same
vessel (7). An FFR value 0.75 is linked to ischemia on
stress testing with high sensitiv-
ity and specificity (6,7). Addi-
tionally, among patients with
symptomatic ischemia, an FFR
value 0.75 can be useful in
identifying those who might
benefit from revascularization
for symptom improvement, al-
though those with values 0.80
seem to also accrue benefit (6,8).
A variety of pharmacological
agents have been used to induce
coronary artery hyperemia (9).
Adenosine is the standard agent
used for FFR measurement in
practice and landmark clinical
trials (5,8). The principle mech-
anism underlying its utility for
stress imaging and FFR assess-
ment is through hyperemia in-
duced by activation of A2A adenosine receptors (10,11).
Unfortunately, concurrent activation of A1, A2B, and A3
receptors can produce short-term undesirable effects, such as
chest pain, dyspnea, bronchospasm, high-grade atrioven-
tricular block, and hypotension (9,12–14).
Recently, the U.S. Food and Drug Administration
approved regadenoson, a selective A2A receptor agonist
or use as a pharmacological stress agent in myocardial
erfusion imaging (15,16). Regadenoson has advantages
ver adenosine by providing a short but slightly longer
uration of action, a simpler mode of administration (a
ingle, weight-unadjusted intravenous bolus dose), and
omparable efficacy with fewer side effects (16,17). Ad-
itionally, the degree of hyperemia is similar, as demon-
trated by invasive coronary blood flow assessment in
Abbreviations
and Acronyms
BP  blood pressure
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CAS  coronary artery
stenosis
FFR  fractional flow
reserve
HR  heart rate
Pa  aortic pressure
proximal)
CI  percutaneous
coronary intervention
Pd  post-stenotic pressure
distal)umans (18). cAlthough the efficacy of regadenoson in myocardial
erfusion imaging has become evident, it remains to be seen
hether it can be used for the assessment of FFR. Accord-
ngly, the aim of this prospective study was to evaluate the
fficacy of regadenoson, in comparison with adenosine, for
ssessing FFR.
ethods
Patient population. The patient population consisted of 25
consecutive patients presenting for elective coronary angiog-
raphy who underwent a clinically indicated FFR assessment
for a de novo CAS of intermediate severity (25 lesions)
between July 2009 and December 2010. In this study, FFR
was measured only when uncertainty with regard to the
hemodynamic significance of the lesion existed and when
the results would influence the management strategy. An
intermediate CAS was defined as a 40% to 70% stenosis on
the basis of visual estimation during angiography. Specific
inclusion and exclusion criteria exactly mirror criteria used
in the ADVANCE (ADenosine Versus regAdenosoN
Comparative Evaluation) phase 3 multicenter international
clinical trial using regadenoson (16). In accordance with
FAME (Fractional Flow Reserve versus Angiography for
Multivessel Evaluation) trial criteria, an FFR cutoff of 0.80
or less after initial adenosine administration was used to
decide whether to perform percutaneous coronary interven-
tion (PCI) of the lesion or refer for coronary artery bypass
grafting (CABG) (8).
Study design. The primary endpoint of this prospective,
pen-label study was to compare intrapatient variability of
FR measurements with: 1) an IV infusion of adenosine
Adenoscan, Astellas Pharma, Inc., Deerfield, Illinois) fol-
owed by, 2) a single intravenous (IV) bolus administration
f regadenoson (Lexiscan, Astellas Pharma). The secondary
utcomes evaluated changes in hemodynamic parameters
heart rate [HR], blood pressure [BP], and maximum
rans-stenotic pressure gradient), time to steady-state FFR,
nd the side effect profile with the 2 hyperemic agents. This
tudy was funded by the University of Pittsburgh Heart and
ascular Institute and received approval by the University
nstitutional Review Board. Written informed consent was
rovided by all patients enrolled in this study.
Procedural details. Patients were pre-medicated before car-
iac catheterization with aspirin (81 mg), IV fentanyl (25
g), and IV midazolam (1 mg). Angiography with 5-F or
-F coronary catheters was performed in multiple views.
he HR, arterial BP, and heart rhythm were continuously
onitored throughout the procedure. If FFR was clinically
ndicated, heparin was given (maximum 5,000 U) for a goal
ctivated clotting time of 200 to 250 s. A 0.014-inch
iameter, high-fidelity pressure-recording guidewire (Pres-
ureWire, Radi Medical Systems, Uppsala, Sweden; Vol-
ano Prime Wire, Volcano Corp., Rancho Cordova, Cali-
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1087fornia) was externally calibrated and then advanced freely
through the catheter into the central aorta, as previously
described (7). From this position, equalization of pressures
from the aorta and pressure wire was confirmed. The
coronary artery was then re-engaged with an end-hole
diagnostic or guide catheter, and then the pressure wire was
advanced into the artery with the pressure sensor placed
distal to the CAS. Careful attention was paid to avoid
arterial pressure dampening or variation of the measured
coronary catheter pressure. In all cases, the catheter was
slightly disengaged from the ostium of the coronary artery
and then flushed with 10 ml of heparinized saline solution.
Mean and phasic distal coronary (Pd) and aortic (Pa)
ressure was measured at baseline and after maximal hyper-
mia, with the pharmacological protocol described in the
ollowing text. Pressure signals were continuously recorded
t a paper speed of 25 mm/s for the calculation of FFR.
Pharmacological protocol. After confirming suitable pres-
ure wire position distal to the stenosis, a peripheral IV
nfusion of adenosine (140 g/kg/min) was given through a
ate-controlled infusion pump. This was continued until
teady-state hyperemia (persistent FFR nadir) was reached
nd for a minimum of 2 min. After termination of the
nfusion, the IV line was flushed with 10 ml normal saline
o clear any residual adenosine. Next, the pressure ratio
Pd/Pa) was monitored for a minimum of 5 min and until it
returned to the baseline level. When this was achieved, a
peripheral IV bolus of regadenoson (400 g) was adminis-
ered over 10 s. The FFR measurements were recorded in an
nblinded fashion during steady-state hyperemia after
denosine and regadenoson administration. The FFR was
easured on a beat-to-beat basis and not averaged over a
eries of beats. If beat-to-beat variations in FFR occurred
uring maximal hyperemia, the lowest FFR value was
ecorded and online pressure tracings were reviewed to
onfirm accuracy. Additionally, HR, BP, heart rhythm, and
ide effects were continuously monitored and recorded at
aseline and during maximal hyperemia. Trans-stenotic
ressure gradient, defined as Pa  Pd, was measured during
teady-state hyperemia. The time to reach steady-state
yperemia for each agent was recorded. After completion of
tudy protocol, the patient received PCI, a referral for
ABG, or medical therapy on the basis of the overall
ndings.
Statistical analysis. Data are presented as mean  SD. The
Student paired t test was used to compare hemodynamic
parameters (systolic BP, diastolic BP, and HR) from base-
line to maximal hyperemia after dosing with adenosine and
regadenoson and to compare mean overall change in hemo-
dynamic status and adverse events between the 2 hyperemic
stimuli. A linear regression analysis with Pearson correlation
coefficient and 2-tailed test for significance was performed
for FFR and trans-stenotic pressure gradient data derived
from both hyperemic stimuli. Results were consideredstatistically significant at p  0.05. Statistical analysis was
performed with SPSS 15 software (SPSS, Inc., Chicago,
Illinois).
Results
Study patients. All 25 patients were included in the analy-
is. Indications for diagnostic cardiac catheterization in-
luded an abnormal functional stress test result (n 18), the
resence of typical angina (n  5), or an abnormal coronary
omputed tomography angiogram (n  2). Baseline char-
cteristics of the entire cohort are described in Table 1. For
ach patient, only 1 CAS (25 total lesions) was assessed by
FR. Two patients had prior CABG; however, only lesions
Table 1. Baseline Characteristics of Study Population (N  25)
Age, yrs 63 11
Male/female 13 (52)/12 (48)
Race
Caucasian 22 (88)
Black 2 (8)
Middle-Eastern 1 (4)
Weight (kg) 88.1 21.3
Body mass index (kg/m2) 30.0 5.7
Clinical factors
Family history of premature CAD 6 (24)
Active smoking 8 (32)
Known CAD 10 (40)
Prior MI 5 (20)
Prior PCI 8 (32)
Prior CABG 2 (8)
COPD 5 (20)
Hypertension 21 (84)
Dyslipidemia 21 (84)
Diabetes mellitus 6 (24)
CVA 3 (12)
Arrhythmia 3 (12)
Ventricular tachycardia 1 (4)
Atrial ﬁbrillation 2 (8)
LV ejection fraction (%) 58 11
Angiographic factors
Multivessel CAD 9 (36)
Target vessel
Left main 3 (12)
Left anterior descending 12 (48)
Left circumﬂex 2 (8)
Ramus intermedius 1 (4)
Right coronary artery 7 (28)
Percent stenosis (%) 58 9
TIMI ﬂow grade 3 0
Values are mean SD or n (%).
CABG  coronary artery bypass grafting; CAD  coronary artery disease; COPD  chronic
obstructive pulmonary disease; CVA  cerebrovascular accident; LV  left ventricular; MI 
myocardial infarction; PCI percutaneous coronary intervention; TIMI Thrombolysis In Myo-cardial Infarction.
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1088accessed directly through the origin of the native right or
left coronary artery without a bypass graft were evaluated.
All vessels containing the target lesion had pre-procedural
Thrombolysis In Myocardial Infarction flow grade 3. No
collateral flow was present. Nine patients had multivessel
CAD (70% stenosis in at least 2 major vessels, excluding
target vessel). However, FFR was only performed in vessels
with a single lesion of intermediate severity (mean percent-
age stenosis by visual estimation 58%  9% [range 40% to
0%]). Successful cannulation of the pressure-recording
uidewire beyond the CAS was achieved in all patients
PressureWire, Radi Medical Systems [n  23]; Volcano
rime Wire, Volcano Corp. [n  2]). The target lesion was
ost commonly located in the left anterior descending (n
2), followed by the right coronary artery (n  7), left main
n  3), left circumflex (n  2), and ramus intermedius
n  1). No procedure-related complications occurred.
IV adenosine infusion versus IV regadenoson bolus for measuring
FFR. The mean FFR after IV adenosine infusion and re-
adenoson bolus was 0.810  0.089 and 0.805  0.091,
Table 2. Individual FFR Measurements During Maximal Hyperemia With
IV Adenosine Infusion and IV Regadenoson Bolus
Patient # Sex
Age
(Yrs)
Coronary
Artery
Adenosine
FFR
Regadenoson
FFR
1 Female 82 LM 0.95 0.95
2 Female 52 LAD 0.75 0.75
3 Female 46 LM 0.90 0.90
4 Female 64 LCX 0.79 0.79
5 Male 66 LAD 0.63 0.61
6 Male 45 RCA 0.74 0.74
7 Female 63 RCA 0.92 0.93
8 Male 70 LAD 0.72 0.72
9 Male 53 LAD 0.77 0.76
10 Female 52 LAD 0.83 0.82
11 Male 64 RCA 0.93 0.92
12 Male 64 LAD 0.67 0.68
13 Female 58 RCA 0.87 0.87
14 Female 79 LCX 0.97 0.97
15 Female 68 LAD 0.78 0.77
16 Male 79 LAD 0.74 0.74
17 Female 53 LAD 0.87 0.85
18 Female 49 RI 0.77 0.71
19 Male 80 LM 0.81 0.83
20 Male 66 LAD 0.69 0.71
21 Male 53 LAD 0.82 0.83
22 Male 52 RCA 0.86 0.85
23 Male 72 LAD 0.77 0.77
24 Female 73 RCA 0.88 0.88
25 Male 63 RCA 0.77 0.78
Mean  SD 0.81 0.09 0.81 0.09
FFR  fractional flow reserve; LAD  left anterior descending; LCX  left circumflex; LM  left
main; RCA right coronary artery; RI ramus intermedius.respectively (Table 2). There was a strong and linearcorrelation between the 2 hyperemic stimuli (R  0.985,
 1.0024x  0.0048; p  0.001) (Fig. 1). A hemody-
amically significant lesion, defined as an FFR 0.80, was
resent in 13 patients (52%). There was no reclassification
f hemodynamic significance between adenosine and re-
adenoson. To evaluate whether more stringent criteria for
emodynamic significance (FFR 0.75) would result in
ignificant reclassification, we found that this occurred in
nly 1 patient having an FFR of 0.77 and 0.71 after
dministration of adenosine and regadenoson, respectively.
mong the 13 patients with an FFR 0.80, 5 patients
nderwent CABG, and 8 patients had PCI of the culprit
esion. The remaining 12 patients without hemodynamically
ignificant lesions were treated medically.
Hemodynamic observations. Simultaneous recording of the
mean post-stenotic pressure (Pd) and mean aortic pressure
Pa) was achieved during maximal hyperemia with adeno-
sine and regadenoson. The trans-stenotic pressure gradient
(Pa  Pd) at maximal hyperemia revealed a strong, linear
orrelation between adenosine and regadenoson (R 
.956, y 1.0575x 0.1832, p 0.001). At baseline, there
were no significant differences in systolic, diastolic, or mean
arterial BP before adenosine or regadenoson dosing (systolic
BP: 140  20 mm Hg vs. 138  21 mm Hg, p  0.437;
diastolic BP 72  10 mm Hg vs. 69  8 mm Hg, p 
0.103; mean arterial BP 95 12 mm Hg vs. 92 11 mm Hg,
p  0.139; adenosine vs. regadenoson), but there was a
significantly higher HR before the administration of re-
gadenoson (68  10 beats/min vs. 71  10 beats/min, p 
0.018; adenosine vs. regadenoson). Systolic, diastolic, and
mean arterial BP decreased from baseline during maximal
hyperemia with both adenosine and regadenoson, whereas
HR increased with each agent (Table 3). The decrease in
diastolic BP was more pronounced in patients receiving
Figure 1. Linear Regression Analysis of Intrapatient FFR
Linear regression analysis of intrapatient fractional ﬂow reserve (FFR) mea-
sured with an IV adenosine infusion and IV regadenoson bolus.
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1089adenosine, compared with regadenoson (11  9 mm Hg
s. 6  8 mm Hg, p  0.008), but there was a similar
decrease in systolic BP (14  16 mm Hg vs. 12  14
mm Hg, p  0.602) and mean arterial BP (12  10 mm
Hg vs. 8  10 mm Hg, p  0.088). There was a trend
toward a higher HR after regadenoson administration,
compared with adenosine (p  0.048). The mean time to
achieve a steady state FFR was shorter with regadenoson,
compared with adenosine (34.0  10.8 s vs. 75.5  26.5 s,
p  0.001).
Side effect proﬁle. No serious events occurred with admin-
istration of either adenosine or regadenoson. All reported
adverse events are described in Table 4. Most events were
brief and self-limiting, except in 1 patient who suffered from
a severe transient headache after receiving regadenoson
(5-min duration). In all patients, except for the 1 with the
severe headache, symptoms were described as more mild
after dosing with regadenoson, compared with adenosine.
The most frequent adverse event occurring with adenosine
was flushing (44%), followed by chest discomfort (32%),
headache (24%), and nausea (20%). With regadenoson, the
most frequent events were chest discomfort (20%), flushing
(16%), and headache (16%). One patient reported a tran-
sient metallic taste in the mouth after regadenoson dosing.
More patients reported having no adverse events after
receiving regadenoson (n  13), compared with adenosine
Table 3. Hemodynamic Parameters at Baseline and After Hyperemia Induc
Hemodynamic
Parameter
IV Adenosine Infusion
Baseline* Hyperemia† p Value ‡ (Range)
SBP (mm Hg) 140 20 126 22 0.001 14 16 (46 to 13
DBP (mm Hg) 72 10 61 9 0.001 11 9.0 (28 to 3
MAP (mm Hg) 95 12 83 13 0.001 12 10 (33 to 6)
HR (beats/min) 68 10 75 13 0.001 8 10 (12 to 41
Values are mean SD. *Baseline refers to hemodynamic status before administering hyperemic sti
in hemodynamic status from baseline to peak. §P of  is comparing  from hyperemia with baselin
DBP diastolic blood pressure; HR heart rate; IV intravenous; MAPmean arterial pressure
Table 4. Adverse Events After Dosing With Adenosine and Regadenoson
Adverse Events
Adenosine
(n  25)
Regadenoson
(n  25) p Value
No event 8 (32) 13 (52) 0.057
Any event 17 (68) 12 (48) 0.057
Flushing 11 (44) 4 (16) 0.005
Dyspnea 4 (16) 1 (4) 0.083
Headache 6 (24) 4 (16) 0.161
Chest discomfort 8 (32) 5 (20) 0.083
Nausea 5 (20) 0 (0) 0.022
Diaphoresis 1 (4) 1 (4) NA
Metallic taste 0 (0) 1 (4) NAiValues are n (%).(n  8). There were no reported occurrences of second- or
hird-degree atrioventricular block with either agent. One
atient had a first-degree atrioventricular block at baseline
hat was stable throughout the study. Additionally, there
ere no cases of bronchospasm, and the administration of
minophylline to reverse adverse events was not required.
iscussion
This study demonstrates that a single, peripheral IV bolus
dose of regadenoson (400 g) provides an excellent corre-
lation in FFR, compared with a continuous 2-min infusion
of IV adenosine (140 g/kg/min). The use of regadenoson
bviated the need for an infusion pump- and weight-based
osing, thus simplifying drug delivery. Furthermore, most
atients seemed to tolerate regadenoson better and reported
ewer and more tolerable side effects from its administra-
ion, compared with adenosine. Regadenoson, a selective
2A receptor agonist, currently has U.S. Food and Drug
dministration approval for use as a pharmacological stress
gent in radionuclide imaging. Our results suggest that
urthering this indication to include its use in measuring
FR should be considered.
Obtaining a reliable FFR measurement is dependent
pon inducing maximal coronary vasodilatation. Failure to
nduce maximal hyperemia will result in an underestimation
f the pressure gradient across a stenosis (giving an artifi-
ially high FFR) and thus an underestimation of stenosis
everity. We show that regadenoson has a strong linear
orrelation to adenosine for lesion assessment by FFR (R 
.985, p  0.001). Of clinical relevance is the finding that
se of either agent did not result in the reclassification of
emodynamic significance when using the FAME trial
riteria (FFR 0.80) (8).
Several pharmacological agents have been used to induce
oronary hyperemia, including adenosine, papaverine, di-
yridamole, 5=-triphosphate, dobutamine, and sodium ni-
roprusside (19–25). Among these agents, papaverine was
he historical “gold standard” in the assessment of coronary
ow velocity. Like regadenoson, intracoronary papaverine
IV Adenosine Infusion and IV Regadenoson Bolus
IV Regadenoson Bolus
p Value of §Baseline Hyperemia p Value  (Range)
138 21 127 23 0.001 12 14 (41 to 10) 0.602
69 8 63 10 0.001 6 8 (22 to 6) 0.008
92 11 85 14 0.001 8 10 (26 to 7) 0.088
71 10 82 12 0.001 12 10 (7 to 34) 0.048
yperemia refers to hemodynamic status during maximal hyperemia. ‡ refers to the mean change
egadenoson and adenosine.
systolic blood pressure.ed by
)
)
)
muli. †H
e with rnduces maximal coronary hyperemia quickly (10 to 30 s),
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1090but the duration of steady-state hyperemia is shorter (45 to
60 s) (22,26,27). It also has a similar linear correlation with
FFR and trans-stenotic pressure gradient when compared
with an IV infusion of adenosine (26). The concern with
papaverine use involved QT-prolongation and the subse-
quent risk of polymorphic ventricular tachycardia or fibril-
lation (28–30).
We observed a faster onset of maximal hyperemia (FFR
nadir) with a bolus dose of regadenoson (mean 34 s),
compared with IV adenosine infusion (mean 76 s). How-
ever, we did not record the duration of maximal hyperemia
induced by regadenoson to minimize the procedural time.
Biochemical binding studies have revealed regadenoson to
have a half-life of approximately 5.2  0.2 min (31–33).
This prolonged half-life compared with adenosine (seconds)
was the primary reason we chose to measure FFR with
regadenoson last. The efficacy of regadenoson to achieve a
quick and robust steady-state hyperemia was established by
comparison of coronary flow velocities induced by adenosine
in both canine models and humans (18,34,35).
Lieu et al. (18) compared the coronary blood flow velocity
achieved by escalating bolus doses of IV regadenoson (10 to
500 g) with intracoronary adenosine (18 g) among 34
patients presenting for a clinically indicated cardiac cathe-
terization. With intracoronary adenosine, there was a tran-
sient increase in coronary blood flow velocity of 3.1 
0.44-fold above baseline that occurred in approximately
30 s. At regadenoson doses of 100 g or greater, the peak
increase in flow velocity was similar to that caused by 18 g
of adenosine. With the same dose used in our study (400
g), flow velocity increased to 3.1  0.52-fold above
baseline. Peak flow occurred in 33 s (range 20 to 40 s) and
was independent of dose, just as we observed. The duration
of 2- and 2.5-fold or greater flow after 400 g of regade-
noson was 8.5 min and 2.3 min, respectively. On the basis
of this evidence, regadenoson is likely to be effective for
assessing the hemodynamic significance of tandem lesions,
but this needs to be evaluated in future studies.
Although regadenoson has previously been compared
with intracoronary adenosine for inducing coronary hyper-
emia, we felt that an IV adenosine infusion would provide a
more reliable steady-state hyperemia for the purpose of this
study. It has been reported that intracoronary adenosine
fails to produce maximal hyperemia in approximately 8% to
10% of cases (36,37). Incremental dose escalation might be
required to avoid deferring PCI in patients with an FFR
that is falsely above the hemodynamic threshold, and
pressure pull-backs are not possible with this dosing regi-
men (36).
Although adenosine is a safe and generally well-tolerated
hyperemic agent (through its activation of A2A receptors),
transient adverse events are associated with its nonselective
activation of the G-protein–coupled adenosine receptor
subtypes, A1, A2b, and A3 (9,12–14). These side effects caninclude chest pain and dyspnea, with serious events, includ-
ing bronchospasm and high-grade atrioventricular block.
Regadenoson was developed, because of these undesirable
effects, and shown to be a useful hyperemic agent in stress
myocardial perfusion imaging (16,17).
The chemical structure of regadenoson, a 2-[N-1-(4-N-
methylcarboxamidopyrazolyl)]-adenosine derivative, pro-
vides it with good potency and functional selectivity for the
A2A adenosine receptor versus A1, A2B, and A3 adenosine
receptors (32,33,38). Numerous clinical studies, including
our own, have revealed that hemodynamic effects of regade-
noson include a transient decrease in BP and increase in HR
(16–18). The degree of BP lowering seems to be similar
between adenosine and regadenoson, whereas the rise in
HR might be more pronounced with the latter (16–18,39).
We found a similar reduction in systolic and mean arterial
BP but a more pronounced reduction of diastolic BP after
administering adenosine, compared with regadenoson
(Table 4). It has been suggested that the sinus tachycardia
caused by regadenoson might be a result of direct stimula-
tion of chemoreceptors, resulting in sympathoexcitation and
release of catecholamines (40). We observed an increased
HR with both agents; however, there was a trend toward a
greater rise with regadenoson. This might be because the
sympathoexcitation induced by adenosine might not have
fully resolved by the time regadenoson was given.
In our study, side effects were judged to be less severe
(with the exception of 1 patient with a severe, transient
headache) with regadenoson, compared with adenosine,
which is consistent with phase 3 clinical studies (16,17,39).
Although adenosine is contraindicated in patients with
reactive airway disease, there is a growing body of evidence
suggesting that regadenoson might be safely used in patients
with mild or moderate reactive airway disease and chronic
obstructive pulmonary disease (41–43). Twenty percent of
our patients had chronic obstructive pulmonary disease, and
symptoms were well-tolerated in these patients. Finally, the
use of aminophylline, an adenosine receptor antagonist, was
not required to mitigate symptoms in our patients and was
likewise seldom used in clinical trials (16,17).
Study limitations. We recruited stable patients needing a
clinically indicated cardiac catheterization. Given the “off-
label” use of regadenoson in this study, we chose exclusion
criteria that mirrored prior clinical studies using regade-
noson (16). Therefore, we cannot extrapolate our results
beyond our study population. Additionally, we chose to
compare the effects of regadenoson with a 2-min IV
infusion of adenosine (140 g/kg/min). Equivalent coro-
nary flow velocities with intracoronary adenosine (18 g)
and regadenoson (as low as 100 g) have been documented
in human subjects (18). Whether lower doses of regade-
noson would have achieved similar results remains uncer-
tain. Finally, the side effect profile of our study patients
must be interpreted with caution. Specifically, our adverse
b
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conclusions. Also, although all patients were awake
throughout the study, they did receive prior conscious
sedating medications that might alter their perception of
symptoms.
Conclusions
Our results demonstrate that a single IV bolus of regade-
noson (400 g) is similarly effective to IV adenosine (140
g/kg/min) for measuring FFR and identifying those le-
sions that are hemodynamically significant. Regadenoson
has the benefit of single, weight-unadjusted bolus dosing
and might mitigate undesirable side effects due its selectivity
toward the A2A receptor. Given its ease of use, it is likely to
e an attractive option for measuring FFR. Before advocat-
ng its widespread use, however, further studies are war-
anted to confirm and expand upon our results.
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